RxDoctor Payments Data

Francis Strain, MD

Internal Medicine · Baltimore, MDNPI 1588607907

Payments from drug & device makers

$1,765in general payments, 2019–2025

Across 105 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$323
  • Novo Nordisk$240
  • Sanofi-aventis U.S. LLC$186
  • Pfizer$170
  • Merck$114
  • Kowa Pharmaceuticals America, Inc.$96
  • plus $637 from 13 others

What the payments were for

  • Food & beverage$1,765100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,765 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$177,226
Medicare patients
1,235
Services billed
3,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate97$114,946
EliquisApixaban88$99,738
JardianceEmpagliflozin44$63,694
OzempicSemaglutide39$60,450
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$28,643
FarxigaDapagliflozin Propanediol18$28,438
TrulicityDulaglutide13$25,731
EntrestoSacubitril/Valsartan28$20,461
LinzessLinaclotide18$15,766
XareltoRivaroxaban14$12,932
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$11,128
Janumet XrSitagliptin Phos/Metformin Hcl14$10,849
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$9,803
MyrbetriqMirabegron12$9,487
Rosuvastatin Calcium300$8,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$114$125,795111 claims
PfizerEliquis$170$99,73888 claims
Boehringer IngelheimJardiance, Tradjenta$56$69,98956 claims
Novo NordiskOzempic$240$60,45039 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$76$50,07783 claims
AstraZenecaFarxiga$323$28,43818 claims
Lilly USA, LLCTrulicity$64$25,73113 claims
NovartisEntresto$66$20,46128 claims
AbbVieLinzess, Synthroid$15$18,12150 claims
Astellas Pharma US IncMyrbetriq$34$9,48712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →